TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 34.57

Change

+0.73 (+2.16)%

Market Cap

USD 1.19B

Volume

0.41M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-0.22 (-0.06%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

-7.48 (-0.84%)

USD 106.98B
MRNA Moderna Inc

+1.79 (+1.69%)

USD 38.83B
ARGX argenx NV ADR

+4.20 (+1.14%)

USD 22.08B
BNTX BioNTech SE

+0.50 (+0.58%)

USD 21.93B
GMAB Genmab AS

+0.69 (+2.51%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-0.40 (-0.28%)

USD 18.18B
RPRX Royalty Pharma Plc

-0.11 (-0.39%)

USD 18.18B
BGNE BeiGene Ltd

+5.02 (+3.38%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-1.26 (-1.53%)

USD 16.06B

ETFs Containing TARS

SLX VanEck Steel ETF 4.79 % 0.56 %

+0.45 (+0.00%)

USD 0.11B
XME SPDR® S&P Metals and Min.. 4.33 % 0.35 %

+0.52 (+0.00%)

USD 2.04B
BBP Virtus LifeSci Biotech Pr.. 3.55 % 0.79 %

+0.58 (+0.00%)

USD 0.02B
FXZ First Trust Materials Alp.. 3.38 % 0.64 %

+0.38 (+0.00%)

USD 0.44B
TQSM:CA TD Q U.S. Small-Mid-Cap E.. 2.00 % 0.00 %

+0.11 (+0.00%)

CAD 0.19B
IJK iShares S&P Mid-Cap 400 G.. 1.38 % 0.24 %

+0.26 (+0.00%)

USD 9.44B
MDYG SPDR® S&P 400 Mid Cap Gr.. 1.32 % 0.15 %

+0.23 (+0.00%)

USD 2.87B
ONEV SPDR® Russell 1000 Low V.. 0.83 % 0.20 %

-0.05 (0.00%)

USD 0.62B
DEUS Xtrackers Russell US Mult.. 0.81 % 0.18 %

+0.16 (+0.00%)

USD 0.15B
ONEO SPDR® Russell 1000 Momen.. 0.76 % 0.20 %

+0.30 (+0.00%)

USD 0.14B
IJH iShares Core S&P Mid-Cap .. 0.72 % 0.07 %

+0.14 (+0.00%)

USD 85.06B
MDY SPDR® S&P MIDCAP 400 ETF.. 0.71 % 0.24 %

+1.52 (+0.00%)

USD 22.34B
SPY4:LSE SSgA SPDR ETFs Europe I P.. 0.70 % 0.00 %

+0.75 (+0.00%)

USD 1.99B
SPY4:PA SSgA SPDR S&P 400 US Mid .. 0.70 % 0.00 %

+1.06 (+0.00%)

USD 1.87B
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.70 % 0.00 %

+1.02 (+0.00%)

USD 1.99B
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.70 % 0.00 %

+1.01 (+0.00%)

USD 1.99B
SPMD SPDR Russell Small Cap Co.. 0.69 % 0.06 %

+0.12 (+0.00%)

USD 9.78B
ZMID:CA BMO S&P US Mid Cap Index .. 0.68 % 0.00 %

N/A

N/A
VBR Vanguard Small-Cap Value .. 0.59 % 0.07 %

+0.68 (+0.00%)

USD 55.51B
SMLF iShares MSCI USA Small-Ca.. 0.57 % 0.30 %

+0.26 (+0.00%)

USD 1.00B
MVV ProShares Ultra MidCap400 0.56 % 0.95 %

+0.40 (+0.00%)

USD 0.14B
UMDD ProShares UltraPro MidCap.. 0.47 % 0.95 %

+0.24 (+0.00%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 70.72% 84% B 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.72% 84% B 93% A
Trailing 12 Months  
Capital Gain 170.92% 92% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 170.92% 92% A 96% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.98% 51% F 32% F
Dividend Return -5.98% 51% F 31% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.04% 70% C- 47% F
Risk Adjusted Return -15.71% 49% F 33% F
Market Capitalization 1.19B 82% B 74% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector